Imbrium Therapeutics L.P. (“Imbrium”), a clinical-stage biopharmaceutical company, is presenting pipeline developments at the BIO International Convention on Wednesday, June 18, at 9:15 a.m ...

STAMFORD, Conn., June 16, 2025--Imbrium Therapeutics L.P. ("Imbrium"), a clinical-stage biopharmaceutical company, is presenting pipeline developments at the BIO International Convention on ...

DelveInsight's Clostridium Difficile Infections pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Clostridium Difficile Infections treatment.

Oligonucleotides are short chains of nucleic acid molecules that can be used to treat or manage a variety of diseases. Oligonucleotides are being increasingly explored for a variety of therapeutic ...

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

DelveInsight's Glaucoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Glaucoma treatment.

DelveInsight's Gastroparesis pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Gastroparesis treatment.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, Endosome Therapy StemXO ...

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.